SCYNEXIS (SCYX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference highlights

• Presented a corporate update, focusing on antifungal product development and strategic partnerships.

• Emphasized the partnership with GSK, with a deal value up to $448 million plus royalties, and $150 million already received.

• Outlined the completion of key studies (FURI, CARES, NATURE) and delivery of clinical study reports, triggering a $10 million milestone.

• Discussed the ongoing MARIO study, currently on hold due to manufacturing compliance, with plans to request FDA clearance to resume next quarter.

• Highlighted a strong balance sheet with over $83.7 million in cash and a runway exceeding two years.

Industry and market analysis

• Noted the limited number of antifungal drug families and the high mortality rates of invasive fungal diseases.

• Stressed the growing at-risk population due to increased use of immunosuppressive therapies and cancer treatments.

• Identified a significant need for new antifungals, with only azoles and fungerps available orally.

• Cited global health organizations (WHO, CDC, BARDA) prioritizing antifungal development, especially for multi-drug resistant pathogens.

• Estimated the market opportunity for current and next-generation products at over $500 million.

Product pipeline and development plans

• Focused on maximizing the ibrexafungerp opportunity with GSK and supporting commercialization efforts.

• Advancing next-generation fungerp (SCY-247), with first-in-human studies planned by year-end.

• Developing SCY-247 in both oral and IV formulations to address unmet needs in invasive fungal diseases.

• SCY-247 expected to have improved tissue penetration and reduced drug-drug interactions.

• Anticipates regulatory designations (QIDP, Orphan Drug, Fast Track) to secure at least ten years of exclusivity.